{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:21:44Z","timestamp":1787739704892,"version":"build-2784847793"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014835","name":"Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105856","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:24:27Z","timestamp":1761751467000},"page":"105856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study"],"prefix":"10.1016","volume":"10","author":[{"given":"E.","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vingiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tamborini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Caspani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Resteghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nuzzolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Buriolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.D.","family":"Locati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.105856_bib1","article-title":"The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading","volume":"30","author":"Juhlin","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105856_bib2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105856_bib3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105856_bib4","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105856_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105856_bib6","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0068","article-title":"Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice","volume":"12","author":"Capdevila","year":"2023","journal-title":"Eur Thyroid J"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105856_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105856_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105856_bib9","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105856_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105856_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105856_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105856_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105856_bib14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105856_bib15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.path.2019.08.002","article-title":"Molecular alterations in thyroid carcinoma","volume":"12","author":"Al Rasheed","year":"2019","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105856_bib16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41467-023-36922-1","article-title":"Recapitulating thyroid cancer histotypes through engineering embryonic stem cells","volume":"14","author":"Veschi","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105856_bib17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105856_bib18","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105856_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.929091","article-title":"What is the status of immunotherapy in thyroid neoplasms?","volume":"13","author":"Garcia-Alvarez","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105856_bib20","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105856_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12020-023-03610-5","article-title":"Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe","volume":"83","author":"de la Fouchardi\u00e8re","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.esmoop.2025.105856_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejca.2018.06.035","article-title":"A pooled analysis of published, basket trials in cancer medicine","volume":"101","author":"Hazim","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105856_bib23","article-title":"Molecular tumor board as a clinical tool for converting molecular data Into real-world patient care","volume":"7","author":"Vingiani","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105856_bib24","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105856_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-021-00905-8","article-title":"DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma","volume":"35","author":"Gonz\u00e1lez","year":"2022","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105856_bib26","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105856_bib27","article-title":"Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): a novel platform umbrella trial","volume":"39","author":"Drilon","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105856_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102447","article-title":"Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial","volume":"69","author":"Shimoi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.esmoop.2025.105856_bib29","article-title":"Response to BRAF and MEK inhibitors in BRAF Thr599dup-mutated melanoma","volume":"6","author":"Oberl\u00e9","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105856_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00432-024-05675-9","article-title":"BRAF\/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report","volume":"150","author":"Jiang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105856_bib31","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105856_bib32","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2025.105856_bib33","article-title":"1646MO Phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma","volume":"33","author":"Dierks","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105856_bib34","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1200\/JCO.2023.41.16_suppl.6091","article-title":"Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC)","volume":"41","author":"Cabanillas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105856_bib35","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7900","key":"10.1016\/j.esmoop.2025.105856_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04451-4","article-title":"Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers","volume":"603","author":"Kobayashi","year":"2022","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105856_bib37","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial evidence for the efficacy of naporafenib in combination with trametinib in NRAS-mutant melanoma: results from the expansion arm of a phase Ib, open-label study","volume":"41","author":"de Braud","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105856_bib38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105856_bib39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/oncolo\/oyad149","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor for the treatment of FGFR-aberrant tumors","volume":"28","author":"Javle","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105856_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.4c00379","article-title":"Discovery of rezatapopt (PC14586), a first-in-class, small-molecule reactivator of p53 Y220C mutant in development","volume":"16","author":"Vu","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105856_bib41","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2022.40.16_suppl.3003","article-title":"First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105856_bib42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105856_bib43","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105856_bib44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.esmoop.2025.105856_bib45","article-title":"Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a comprehensive profiling program: impact on precision medicine oncology","volume":"6","author":"Martin-Romano","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105856_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ando.2024.02.001","article-title":"RET kinase inhibitors for the treatment of RET-altered thyroid cancers: current knowledge and future directions","volume":"85","author":"Hamidi","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.esmoop.2025.105856_bib47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cancergen.2022.03.002","article-title":"TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults","volume":"264-265","author":"Harada","year":"2022","journal-title":"Cancer Genet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105856_bib48","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2023.1379","article-title":"Diagnosis and management of tropomyosin receptor kinase fusion-positive thyroid carcinomas: a review","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105856_bib49","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105856_bib50","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105856_bib51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105856_bib52","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105856_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102981","article-title":"The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology","volume":"9","author":"Kubo","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105856_bib54","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41591-025-03918-x","article-title":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial","volume":"31","author":"Marchetti","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105856_bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-024-02385-7","article-title":"Common skin cancers and their association with other non-cutaneous primary malignancies: a review of the literature","volume":"41","author":"Holic","year":"2024","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105856_bib56","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","article-title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105856_bib57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12672-024-00904-6","article-title":"Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials","volume":"15","author":"Wang","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.esmoop.2025.105856_bib58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2022.12.002","article-title":"Current picture of anaplastic thyroid cancer patients\u2019 care and meetable needs: a survey of 94 institutions from the EORTC Endocrine and Head and Neck Cancer Groups","volume":"180","author":"Locati","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105856_bib59","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12020-021-02702-4","article-title":"Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib","volume":"73","author":"Platini","year":"2021","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105856_bib60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03008916211025098","article-title":"Systematic review of health-related quality of life following thyroid cancer","volume":"108","author":"Walshaw","year":"2022","journal-title":"Tumori"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:48:43Z","timestamp":1773265723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017259"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105856","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105856"}}